Published • loading... • Updated
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation
Rosen Law Firm says investors may seek compensation after Disc Medicine’s stock fell 18% following the FDA’s rejection of its bitopertin application.
- The Rosen Law Firm is investigating Disc Medicine regarding potential securities claims, following allegations that Disc Medicine issued materially misleading business information to the investing public.
- On February 13, 2026, the FDA issued a Complete Response Letter regarding Disc Medicine's bitopertin program, stating it could not approve the drug application due to uncertainties requiring additional evidence. Disc Medicine's stock fell 22% that day.
- With a track record of success in securities litigation, The Rosen Law Firm concentrates its practice in securities class actions and encourages investors to select qualified counsel with proven leadership experience.
- Separately, The Rosen Law Firm is investigating TruBridge after the company filed a Notification of Late Filing on March 17, 2026. TruBridge's stock price fell $1.84 per share, or 10.5%, on that announcement.
- Investors interested in joining the class actions may contact Phillip Kim, Esq. toll-free at 866-767-3653, with no out-of-pocket costs through the firm's contingency fee arrangement.
Insights by Ground AI
41 Articles
41 Articles
The Logan Banner+14 Reposted by 14 other sources
Rosen Law Firm Encourages TruBridge, Inc. Investors to Inquire About Securities Class Action Investigation
NEW YORK, Aug. 22, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of TruBridge, Inc. (NASDAQ: TBRG) resulting from allegations that TruBridge may have issued materially…
Coverage Details
Total News Sources41
Leaning Left7Leaning Right4Center25Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
L 20%
C 69%
11%
Factuality
To view factuality data please Upgrade to Premium
